REPORT ID 13431

EMEA (Europe, Middle East and Africa) General Anesthesia Drugs Market Report 2017

Publish Date
21-Nov-17
Pages
112
Format
Electronic (PDF)

In this report, the EMEA General Anesthesia Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K L), revenue (Million USD), market share and growth rate of General Anesthesia Drugs for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA General Anesthesia Drugs market competition by top manufacturers/players, with General Anesthesia Drugs sales volume (K L), price (USD/L), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Astrazeneca
    Fresenius-Kabi
    AbbVie
    Baxter Healthcare
    B.Braun
    Maruishi
    Piramal
    Hikma Pharmaceuticals
    Mylan
    Nhwa
    Hengrui
    Lunan

On the basis of product, this report displays the sales volume (K L), revenue (Million USD), product price (USD/L), market share and growth rate of each type, primarily split into
    Propofol
    Etomidate
    Midazolam
    Sevoflurane
    Isoflurane
    Other

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K L), market share and growth rate of General Anesthesia Drugs for each application, including
    Intravenous Anesthetics
    Inhalational Anesthetics

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) General Anesthesia Drugs Market Report 2017
1 General Anesthesia Drugs Overview
    1.1 Product Overview and Scope of General Anesthesia Drugs
    1.2 Classification of General Anesthesia Drugs
        1.2.1 EMEA General Anesthesia Drugs Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA General Anesthesia Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Propofol
        1.2.4 Etomidate
        1.2.5 Midazolam
        1.2.6 Sevoflurane
        1.2.7 Isoflurane
        1.2.8 Other
    1.3 EMEA General Anesthesia Drugs Market by Application/End Users
        1.3.1 EMEA General Anesthesia Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Intravenous Anesthetics
        1.3.3 Inhalational Anesthetics
    1.4 EMEA General Anesthesia Drugs Market by Region
        1.4.1 EMEA General Anesthesia Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of General Anesthesia Drugs (2012-2022)
        1.5.1 EMEA General Anesthesia Drugs Sales and Growth Rate (2012-2022)
        1.5.2 EMEA General Anesthesia Drugs Revenue and Growth Rate (2012-2022)

2 EMEA General Anesthesia Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA General Anesthesia Drugs Market Competition by Players/Manufacturers
        2.1.1 EMEA General Anesthesia Drugs Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA General Anesthesia Drugs Revenue and Share by Players (2012-2017)
        2.1.3 EMEA General Anesthesia Drugs Sale Price by Players (2012-2017)
    2.2 EMEA General Anesthesia Drugs (Volume and Value) by Type/Product Category
        2.2.1 EMEA General Anesthesia Drugs Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA General Anesthesia Drugs Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA General Anesthesia Drugs Sale Price by Type (2012-2017)
    2.3 EMEA General Anesthesia Drugs (Volume) by Application
    2.4 EMEA General Anesthesia Drugs (Volume and Value) by Region
        2.4.1 EMEA General Anesthesia Drugs Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA General Anesthesia Drugs Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA General Anesthesia Drugs Sales Price by Region (2012-2017)

3 Europe General Anesthesia Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe General Anesthesia Drugs Sales and Value (2012-2017)
        3.1.1 Europe General Anesthesia Drugs Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe General Anesthesia Drugs Revenue and Growth Rate (2012-2017)
    3.2 Europe General Anesthesia Drugs Sales and Market Share by Type
    3.3 Europe General Anesthesia Drugs Sales and Market Share by Application
    3.4 Europe General Anesthesia Drugs Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe General Anesthesia Drugs Sales Volume by Countries (2012-2017)
        3.4.2 Europe General Anesthesia Drugs Revenue by Countries (2012-2017)
        3.4.3 Germany General Anesthesia Drugs Sales and Growth Rate (2012-2017)
        3.4.4 France General Anesthesia Drugs Sales and Growth Rate (2012-2017)
        3.4.5 UK General Anesthesia Drugs Sales and Growth Rate (2012-2017)
        3.4.6 Russia General Anesthesia Drugs Sales and Growth Rate (2012-2017)
        3.4.7 Italy General Anesthesia Drugs Sales and Growth Rate (2012-2017)
        3.4.8 Benelux General Anesthesia Drugs Sales and Growth Rate (2012-2017)

4 Middle East General Anesthesia Drugs (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East General Anesthesia Drugs Sales and Value (2012-2017)
        4.1.1 Middle East General Anesthesia Drugs Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East General Anesthesia Drugs Revenue and Growth Rate (2012-2017)
    4.2 Middle East General Anesthesia Drugs Sales and Market Share by Type
    4.3 Middle East General Anesthesia Drugs Sales and Market Share by Application
    4.4 Middle East General Anesthesia Drugs Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East General Anesthesia Drugs Sales Volume by Countries (2012-2017)
        4.4.2 Middle East General Anesthesia Drugs Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia General Anesthesia Drugs Sales and Growth Rate (2012-2017)
        4.4.4 Israel General Anesthesia Drugs Sales and Growth Rate (2012-2017)
        4.4.5 UAE General Anesthesia Drugs Sales and Growth Rate (2012-2017)
        4.4.6 Iran General Anesthesia Drugs Sales and Growth Rate (2012-2017)

5 Africa General Anesthesia Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa General Anesthesia Drugs Sales and Value (2012-2017)
        5.1.1 Africa General Anesthesia Drugs Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa General Anesthesia Drugs Revenue and Growth Rate (2012-2017)
    5.2 Africa General Anesthesia Drugs Sales and Market Share by Type
    5.3 Africa General Anesthesia Drugs Sales and Market Share by Application
    5.4 Africa General Anesthesia Drugs Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa General Anesthesia Drugs Sales Volume by Countries (2012-2017)
        5.4.2 Africa General Anesthesia Drugs Revenue by Countries (2012-2017)
        5.4.3 South Africa General Anesthesia Drugs Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria General Anesthesia Drugs Sales and Growth Rate (2012-2017)
        5.4.5 Egypt General Anesthesia Drugs Sales and Growth Rate (2012-2017)
        5.4.6 Algeria General Anesthesia Drugs Sales and Growth Rate (2012-2017)

6 EMEA General Anesthesia Drugs Manufacturers/Players Profiles and Sales Data
    6.1 Astrazeneca
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 General Anesthesia Drugs Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Astrazeneca General Anesthesia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Fresenius-Kabi
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 General Anesthesia Drugs Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Fresenius-Kabi General Anesthesia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 AbbVie
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 General Anesthesia Drugs Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 AbbVie General Anesthesia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Baxter Healthcare
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 General Anesthesia Drugs Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Baxter Healthcare General Anesthesia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 B.Braun
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 General Anesthesia Drugs Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 B.Braun General Anesthesia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Maruishi
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 General Anesthesia Drugs Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Maruishi General Anesthesia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Piramal
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 General Anesthesia Drugs Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Piramal General Anesthesia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Hikma Pharmaceuticals
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 General Anesthesia Drugs Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Hikma Pharmaceuticals General Anesthesia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Mylan
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 General Anesthesia Drugs Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Mylan General Anesthesia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Nhwa
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 General Anesthesia Drugs Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Nhwa General Anesthesia Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Hengrui
    6.12 Lunan

7 General Anesthesia Drugs Manufacturing Cost Analysis
    7.1 General Anesthesia Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of General Anesthesia Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 General Anesthesia Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of General Anesthesia Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA General Anesthesia Drugs Market Forecast (2017-2022)
    11.1 EMEA General Anesthesia Drugs Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA General Anesthesia Drugs Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA General Anesthesia Drugs Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA General Anesthesia Drugs Price and Trend Forecast (2017-2022)
    11.2 EMEA General Anesthesia Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe General Anesthesia Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt General Anesthesia Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa General Anesthesia Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA General Anesthesia Drugs Sales Forecast by Type (2017-2022)
    11.7 EMEA General Anesthesia Drugs Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer